- Home
- BCAB vs BGLC Comparison
BCAB vs BGLC Comparison
Compare BCAB & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCAB | BGLC |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | Malaysia |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 10.1M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BCAB | BGLC |
|---|---|---|
| Price | $0.15 | $2.53 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 7.2K |
| Earning Date | 05-05-2026 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 44.19 | ★ 45.78 |
| EPS | ★ N/A | N/A |
| Revenue | $300,000.00 | ★ $9,510,646.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.13 | $0.23 |
| 52 Week High | $1.43 | $15.19 |
Technical Indicators
Market Signals| Indicator | BCAB | BGLC |
|---|---|---|
| Relative Strength Index (RSI) | 38.23 | 51.38 |
| Support Level | $0.13 | $2.12 |
| Resistance Level | $0.21 | $2.73 |
| Average True Range (ATR) | 0.02 | 0.14 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 1.82 | 68.91 |
Price Performance
Historical ComparisonAbout BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About BGLC BioNexus Gene Lab Corp
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.